Market News AIOpen the app

Leerink Partners changed Innate Pharma's rating to Market Perform and cut its price target to $1.

OpinionRead the original at moomoo.com
Bad for IPHA

Leerink Partners cut Innate Pharma from Outperform to Market Perform and lowered its share target to $1. Earlier Phase 1 results showed tumor-fighting activity, but the new downgrade weighs against the company.

IPHA · Innate Pharma S.A.

AI read · Bad for IPHA

The AI's read

This suggests the analyst sees less promise in Innate Pharma's shares after its early study update. Earlier coverage pointed to tumor-fighting activity and stable linkers, but the new downgrade is the clearest signal and weighs against the company.

Get alerts for IPHA

Follow Innate Pharma S.A. (IPHA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IPHA
Free on the App Store and Google Play, or on the web.